Evidence map›Paper›PMID 42877868›Full record

ArticleCase reports in oncology

Carboplatin, Etoposide, and Durvalumab for Extensive-Stage Small Cell Lung Cancer in a Patient Undergoing Maintenance Hemodialysis: A Case Report.

Morimi Fujita, Ninso Matsunaga, Hiroyuki Tsuji, Yosuke Tamura, Kenjiro Tsuruoka, Takahiko Nakamura, Soichiro Ikeda, Yasuhito Fujisaka

Abstract readCase Reports
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Morimi FujitaRespiratory Medicine and Thoracic Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki City, Japan.
Ninso MatsunagaRespiratory Medicine and Thoracic Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki City, Japan.
Hiroyuki TsujiRespiratory Medicine and Thoracic Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki City, Japan.
Yosuke TamuraRespiratory Medicine and Thoracic Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki City, Japan.
Kenjiro TsuruokaRespiratory Medicine and Thoracic Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki City, Japan.
Takahiko NakamuraRespiratory Medicine and Thoracic Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki City, Japan.
Soichiro IkedaRespiratory Medicine and Thoracic Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki City, Japan.
Yasuhito FujisakaRespiratory Medicine and Thoracic Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki City, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients undergoing maintenance hemodialysis exhibit a unique immunological state characterized by chronic inflammation and T-cell dysfunction. Evidence regarding the efficacy and safety of combination chemoimmunotherapy in dialysis patients remains extremely limited. Case Report: We report a case of extensive-stage small cell lung cancer (performance status 1, cT1cN2M1c, stage IVB) in a patient undergoing maintenance hemodialysis who received 4 cycles of carboplatin (300 mg/m Conclusion: Carboplatin, etoposide, and durvalumab can provide meaningful therapeutic benefit even in patients undergoing maintenance hemodialysis when adverse events are appropriately managed.

Indexed as

DurvalumabHemodialysisImmune checkpoint inhibitorsSmall cell lung cancer

Identifiers

PMID42877868
PMCPMC13668068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.